BCDA · BioCardia, Inc.
$0.85
-0.06 (-6.26%)
At close · Jul 24
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed May 15, 2026
Market Cap
$9.67M
Shares
11.37M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Peter Altman | CEO | $493,388 |
| David McClung | CFO | $354,942 |
| Edward Gillis | Senior Vice President of Devices | $251,804 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Peter Altman | CEO | $746,237 |
| David McClung | CFO | $469,469 |
| Edward Gillis | Senior Vice President of Devices | $326,371 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Peter Altman | CEO | $901,897 |
| David McClung | CFO | $565,104 |
| Edward Gillis | Senior Vice President of Devices | $389,704 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Peter Altman | CEO | $1,138,389 |
| David McClung | CFO | $668,409 |
| Edward Gillis | Senior Vice President of Devices | $459,716 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Peter Altman | CEO | $882,849 |
| Edward Gillis | Senior Vice President of Devices | $285,438 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Peter Altman | CEO | $677,501 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Peter Altman | CEO | $1,102,000 |
| Henricus Duckers | Chief Medical Officer | $661,417 |
| David McClung | CFO | $594,982 |